Susquehanna International Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Susquehanna International Group’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-77,501	Closed	-$361K	–	14341
2021 Q4	$361K	Buy	77,501 +49,155	+173%	+$307K	﹤0.01%	10041
2021 Q3	$241K	Sell	28,346 -4,723	-14%	-$66.7K	﹤0.01%	11092
2021 Q2	$543K	Buy	33,069 +6,787	+26%	+$137K	﹤0.01%	9386
2021 Q1	$580K	Sell	26,282 -15,050	-36%	-$410K	﹤0.01%	9150
2020 Q4	$1.28M	Buy	41,332 +29,333	+244%	+$742K	﹤0.01%	6106
2020 Q3	$244K	Sell	11,999 -27,943	-70%	-$491K	﹤0.01%	9122
2020 Q2	$614K	Buy	39,942 +19,185	+92%	+$221K	﹤0.01%	6935
2020 Q1	$161K	Buy	+20,757	New	+$254K	﹤0.01%	8927

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Susquehanna International Group's TCRR Position: Q1 2022 in Review

Susquehanna International Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 77,501 shares — an estimated $361K sold.

Susquehanna International Group first reported a position in TCRR in Q1 2020 and held it in 8 quarters. The position peaked at $1.28M in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

Susquehanna International Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Susquehanna International Group sold 77,501 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $361K.
Susquehanna International Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Susquehanna International Group's TCR2 Therapeutics Inc. Common Stock position peaked at $1.28M in Q4 2020.
94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.